The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
08-Aug-11
$11.0 billion
Target:
Coal and Allied Industries Limited
Acquiror:
Rio Tinto Limited / Mitsubishi Corporation
Advised Coal and Allied Industries Limited, an Australian based coal mining company, in relation to an acquisition proposal from Rio Tinto Limited and Mitsubishi Corporation to acquire all the outstanding shares in the company not already held by Rio Tinto and Mitsubishi
31-Jul-08
$10.3 billion
Target:
TransAlta Corporation
Acquiror:
LS Power Equity Partners / Global Infrastructure Partners
Advised TransAlta Corporation, a power generation and wholesale marketing company, on an unsolicited offer from LS Power Equity Partners / Global Infrastructure Partners
03-May-07
$8.5 billion
Target:
IPSCO Inc.
Acquiror:
SSAB Svenskt Stål AB
Acted as lead financial advisor to SSAB Svenskt Stål AB on its acquisition of IPSCO Inc., a leading Canadian producer of energy tubulars and steel plate in North America with an annual steel making capacity of 4.3 million tons
11-Oct-22
Pending
$7.9 billion
Target:
Westinghouse Electric Company
Acquiror:
Brookfield Renewable Partners and Cameco
Advising the Independent Committee of Brookfield Renewable Partners, the flagship listed renewable power company of Brookfield Asset Management, in consortium with Cameco and other institutional partners, on the acquisition of Westinghouse Electric Company, one of the world’s largest nuclear services businesses, from Brookfield Business Partners
23-Oct-12
$5.7 billion
Target:
Target Corporation’s REDcard credit card assets
Acquiror:
The Toronto-Dominion Bank Group
Advised The Toronto-Dominion Bank Group on its acquisition of Target Corporation’s REDcard credit card assets
02-Oct-07
$4.6 billion
Target:
Nikko Cordial Corporation
Acquiror:
Citigroup, Inc.
Advised Nikko Cordial, one of Japan’s largest securities firms, on its share exchange with Citigroup Inc., which resulted in Citigroup’s acquisition of the remaining 32% of Nikko Cordial that it did not already own
15-Aug-18
$3.9 billion
Target:
Common shares and common share purchase warrants in Canopy Growth
Acquiror:
Constellation Brands
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
29-May-18
$3.5 billion
Target:
Trans Mountain Pipeline system, Trans Mountain Expansion Project and related pipeline and terminal assets
Acquiror:
Government of Canada
Advised the Government of Canada on the acquisition of the Trans Mountain Pipeline system, the Trans Mountain Expansion Project and related pipeline and terminal assets from Kinder Morgan Canada Limited
26-May-15
$2.2 billion
Target:
Nordstrom, Inc. (Credit Card Assets)
Acquiror:
The Toronto-Dominion Bank Group
Advised The Toronto-Dominion Bank Group on its acquisition of Nordstrom, Inc.’s credit card assets
20-Jun-11
$2.0 billion
Target:
Capital Power Income L.P.
Acquiror:
Atlantic Power Corporation
Advised Capital Power Income L.P., a Canadian power trust with a portfolio of 20 power generation assets located in Canada and the United States (total net generating capacity of 1,400 MW), on its sale to Atlantic Power Corporation
29-Dec-10
$1.8 billion
Target:
TOWER Australia Group Limited
Acquiror:
The Dai-ichi Life Insurance Company, Limited
Advised TOWER Australia Group Limited, the largest mono-line life insurance company in Australia, in relation to the offer from The Dai-ichi Life Insurance Company, Limited to acquire all of the shares in TOWER that it does not already own by way of a scheme of arrangement
07-Jun-09
$1.6 billion
Target:
EPCOR Power L.P.
Advised the Independent Committee of the Board of Directors of EPCOR Power L.P., an Alberta-based power trust, on approval of the transfer of its GP interest and 30.6% LP interest from EPCOR Utilities to a newly formed company, Capital Power Corporation
29-Sep-21
~$1.1 billion
Target:
Procaps Group
Acquiror:
Union Acquisition Corp. II (NASDAQ: LATN)
Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
19-Dec-19
$770 million
Target:
Wireless Infrastructure Group Limited
Acquiror:
Brookfield Asset Management
Advised 3i Infrastructure plc on the sale of Wireless Infrastructure Group Limited, a leading independent telecommunications infrastructure provider focusing on mobile towers and indoor connectivity
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
30-Jun-11
$609 million
Target:
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
Acquiror:
Royalty Pharma
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
08-Aug-18
$538 million
Target:
Suncorp Group Limited’s Australian Life Insurance Business
Acquiror:
TAL
Advised TAL, Australia’s largest and leading insurance business that is 100% owned by Dai-ichi Life of Japan, on the acquisition of Suncorp Group Limited’s Australian Life Insurance business
26-Mar-12
$513 million
Target:
ISTA Pharmaceuticals, Inc.
Acquiror:
Bausch + Lomb, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
15-Jun-16
$414 million
Target:
Aegerion Pharmaceuticals
Acquiror:
QLT Inc.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
01-Nov-21
$400 million
Target:
Millennial Lithium
Acquiror:
Lithium Americas
Advised Lithium Americas, a development-stage company with projects in Jujuy, Argentina and Nevada, United States on its acquisition of Millennial Lithium, a Vancouver-based exploration and development company focused on advancing the Pastos Grandes Lithium Project in Argentina
04-Nov-10
~$370 million
Target:
J. Malucelli Participacao em Seguros E Resseguros S.A
Acquiror:
The Travelers Companies, Inc.
Advised Travelers, the largest listed property and casualty insurance company in the U.S., on the acquisition of a ~43% stake in J. Malucelli Participacao em Seguros E Resseguros, the leading surety insurance company in Brazil, through the issue of new common shares (with an option to increase to 49.9% within 18 months)
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories